Get the Stockscreener App
4.16
2.80%
-0.12
After Hours:
4.16
Sana Biotechnology Inc stock is traded at $4.16, with a volume of 2.29M.
It is down -2.80% in the last 24 hours and down -31.24% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
See More
Previous Close:
$4.28
Open:
$4.3
24h Volume:
2.29M
Relative Volume:
1.38
Market Cap:
$915.45M
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-2.2011
EPS:
-1.89
Net Cash Flow:
$-273.61M
1W Performance:
+1.71%
1M Performance:
-31.24%
6M Performance:
-58.40%
1Y Performance:
+7.49%
1-Day Range:
$4.08
$4.34
1-Week Range:
$3.68
$4.445
52-Week Range:
$2.745
$12.00
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference - Yahoo Finance
Recent Insider Activity Could Benefit Sana Biotechnology Inc (SANA) - Knox Daily
Sana Biotechnology Inc (SANA)’s stock price in review: A technical analysis - US Post News
Quarterly Snapshot: Quick and Current Ratios for Sana Biotechnology Inc (SANA) - The Dwinnex
Sana Biotech director Mulligan sells shares worth over $1.19 million - Investing.com
Director Richard Mulligan Sells 300,000 Shares of Sana Biotechno - GuruFocus.com
Sana Biotechnology Inc [SANA] Records 200-Day SMA of $6.71 - Knox Daily
Analysts Provide An Important Insights On Sana Biotechnology Inc (SANA) - Stocks Register
Is Sana Biotechnology Inc (SANA) positioned for future growth? - SETE News
Sana Biotechnology Inc (SANA)’s results reveal risk - US Post News
Massachusetts Financial Services Co. MA Reduces Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - MarketBeat
Integral Health Asset Management LLC Increases Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Integral Health Asset Management LLC Purchases 220,000 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - MarketBeat
Rhumbline Advisers Purchases 25,056 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology (NASDAQ:SANA) Shares Up 9.6% - Defense World
Sana Biotechnology Inc (SANA) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Sana Biotechnology (NASDAQ:SANA) Shares Down 4.1% - MarketBeat
E Fund Management Co. Ltd. Cuts Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology (NASDAQ:SANA) Trading Up 9.6% - MarketBeat
Sana Biotechnology Inc (SANA) deserves closer scrutiny - US Post News
Market Update: Sana Biotechnology Inc (SANA) Sees Negative Movement, Closing at 4.36 - The Dwinnex
There is no way Sana Biotechnology Inc (SANA) can keep these numbers up - SETE News
TD Asset Management Inc Has $2.21 Million Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
TD Asset Management Inc Has $2.21 Million Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) - MarketBeat
Sana Biotech CFO Nathan Hardy to step down in October By Investing.com - Investing.com Australia
Market Update: Sana Biotechnology Inc (SANA) Sees Negative Movement, Closing at 4.53 - The Dwinnex
SANA’s Market Whiplash: 11.03% YTD Rise, -7.55% Plunge in 30 Days - The InvestChronicle
Sana Biotech CFO Nathan Hardy to step down in October - Investing.com
Sana Biotechnology Enters Oversold Territory (SANA) - Nasdaq
Sana Biotechnology CFO Nathan Hardy to Resign - MarketWatch
Sana Biotech CFO Nathan Hardy to step down in October By Investing.com - Investing.com UK
Sana Biotechnology (NASDAQ:SANA) Trading Down 3.4% - MarketBeat
A look into Sana Biotechnology Inc (SANA)’s deeper side - SETE News
Sana Biotechnology Inc (SANA) presents a great opportunity, but the stock is slightly undervalued - US Post News
Sana Biotechnology (NASDAQ:SANA) Trading Down 4.8% - MarketBeat
Closing Strong: Sana Biotechnology Inc (SANA) Ends at 5.50, Down -1.79 from Last Close - The Dwinnex
Wall Street analysts’ outlook for Sana Biotechnology Inc (SANA) - SETE News
Sana Biotechnology Insider Lowered Holding By 14% During Last Year - Simply Wall St
Is it possible to buy Sana Biotechnology Inc(SANA) shares at a good price now? - US Post News
Sana Biotechnology appoints Indian-origin drug developer as Exec VP and Chief Scientific Officerindica News - indica News
The Future of Sana Biotechnology Inc: Analyzing SANA - The InvestChronicle
Director Yang Patrick Y sale 25,000 shares of Sana Biotechnology Inc [SANA] - Knox Daily
Sana Biotechnology (NASDAQ:SANA) Trading Up 7.2% - MarketBeat
Sana Biotechnology to Present at September 2024 Investor Conferences - GlobeNewswire
Sana Biotechnology to Present at September 2024 Investor Conferences - Yahoo Finance UK
Sana Biotechnology names its first chief scientific officer - The Business Journals
Commit To Purchase Sana Biotechnology At $5, Earn 79.7% Annualized Using Options - Nasdaq
Market Watch Highlights: Sana Biotechnology Inc (SANA) Ends on an Downturn Note at 5.78 - The Dwinnex
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer - Quantisnow
Sana Biotechnology (NASDAQ:SANA) Trading Down 4.1% - MarketBeat
Sana Biotechnology appoints new Chief Scientific Officer By Investing.com - Investing.com Australia
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):